Molebogeng X Rangaka1, Robert J Wilkinson2, Andrew Boulle3, Judith R Glynn4, Katherine Fielding4, Gilles van Cutsem5, Katalin A Wilkinson6, Rene Goliath6, Shaheed Mathee7, Eric Goemaere8, Gary Maartens9. 1. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; Clinical Infectious Disease Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; London School of Hygiene & Tropical Medicine, London, UK. Electronic address: mxrangaka@yahoo.co.uk. 2. Clinical Infectious Disease Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Medicine, Imperial College London, London, UK; MRC National Institute for Medical Research, London, UK. 3. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 4. London School of Hygiene & Tropical Medicine, London, UK. 5. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; Médecins Sans Frontières, Cape Town, South Africa. 6. Clinical Infectious Disease Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 7. Provincial Government of the Western Cape, Cape Town, South Africa. 8. Médecins Sans Frontières, Cape Town, South Africa. 9. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
BACKGROUND: Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy. METHODS: For this pragmatic randomised double-blind, placebo-controlled trial in Khayelitsha, South Africa, we randomly assigned (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months (could be completed during 15 months). Randomisation was done with random number generator software. Participants, physicians, and pharmacy staff were masked to group assignment. The primary endpoint was time to development of incident tuberculosis (definite, probable, or possible). We excluded tuberculosis at screening by sputum culture. We did a modified intention-to-treat analysis and excluded all patients randomly assigned to groups who withdrew before receiving study drug or whose baseline sputum culture results suggested prevalent tuberculosis. This study is registered with ClinicalTrials.gov, number NCT00463086. FINDINGS: 1329 participants were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667) between Jan 31, 2008, and Sept 31, 2011, and contributed 3227 person-years of follow-up to the analysis. We recorded 95 incident cases of tuberculosis; 37 were in the isoniazid preventive therapy group (2·3 per 100 person-years, 95% CI 1·6-3·1), and 58 in the placebo group (3·6 per 100 person-years, 2·8-4·7; hazard ratio [HR] 0·63, 95% CI 0·41-0·94). Study drug was discontinued because of grade 3 or 4 raised alanine transaminase concentrations in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 individuals in the placebo group (risk ratio 1·9, 95% CI 0·90-4·09). We noted no evidence that the effect of isoniazid preventive therapy was restricted to patients who were positive on tuberculin skin test or interferon gamma release assay (adjusted HR for patients with negative tests 0·43 [0·21-0·86] and 0·43 [0·20-0·96]; for positive tests 0·86 [0·37-2·00] and 0·55 [0·26-1·24], respectively). INTERPRETATION: Without a more predictive test or a multivariate algorithm that predicts benefit, isoniazid preventive therapy should be recommended to all patients receiving antiretroviral therapy in moderate or high incidence areas irrespective of tuberculin skin test or interferon gamma release assay status. FUNDING: Department of Health of South Africa, the Wellcome Trust, Médecins Sans Frontières, European and Developing Countries Clinical Trials Partnership, Foundation for Innovation and New Diagnostics, the European Union, and Hasso Plattner (Institute of Infectious Diseases and Molecular Medicine, University of Cape Town).
BACKGROUND: Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy. METHODS: For this pragmatic randomised double-blind, placebo-controlled trial in Khayelitsha, South Africa, we randomly assigned (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months (could be completed during 15 months). Randomisation was done with random number generator software. Participants, physicians, and pharmacy staff were masked to group assignment. The primary endpoint was time to development of incident tuberculosis (definite, probable, or possible). We excluded tuberculosis at screening by sputum culture. We did a modified intention-to-treat analysis and excluded all patients randomly assigned to groups who withdrew before receiving study drug or whose baseline sputum culture results suggested prevalent tuberculosis. This study is registered with ClinicalTrials.gov, number NCT00463086. FINDINGS: 1329 participants were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667) between Jan 31, 2008, and Sept 31, 2011, and contributed 3227 person-years of follow-up to the analysis. We recorded 95 incident cases of tuberculosis; 37 were in the isoniazid preventive therapy group (2·3 per 100 person-years, 95% CI 1·6-3·1), and 58 in the placebo group (3·6 per 100 person-years, 2·8-4·7; hazard ratio [HR] 0·63, 95% CI 0·41-0·94). Study drug was discontinued because of grade 3 or 4 raised alanine transaminase concentrations in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 individuals in the placebo group (risk ratio 1·9, 95% CI 0·90-4·09). We noted no evidence that the effect of isoniazid preventive therapy was restricted to patients who were positive on tuberculin skin test or interferon gamma release assay (adjusted HR for patients with negative tests 0·43 [0·21-0·86] and 0·43 [0·20-0·96]; for positive tests 0·86 [0·37-2·00] and 0·55 [0·26-1·24], respectively). INTERPRETATION: Without a more predictive test or a multivariate algorithm that predicts benefit, isoniazid preventive therapy should be recommended to all patients receiving antiretroviral therapy in moderate or high incidence areas irrespective of tuberculin skin test or interferon gamma release assay status. FUNDING: Department of Health of South Africa, the Wellcome Trust, Médecins Sans Frontières, European and Developing Countries Clinical Trials Partnership, Foundation for Innovation and New Diagnostics, the European Union, and Hasso Plattner (Institute of Infectious Diseases and Molecular Medicine, University of Cape Town).
Authors: Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells Journal: Lancet Date: 2011-04-12 Impact factor: 79.321
Authors: Alice Zwerling; Susan van den Hof; Jerod Scholten; Frank Cobelens; Dick Menzies; Madhukar Pai Journal: Thorax Date: 2011-01-12 Impact factor: 9.139
Authors: Stephen D Lawn; Katharina Kranzer; David J Edwards; Matthew McNally; Linda-Gail Bekker; Robin Wood Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Martin W G Brinkhof; Matthias Egger; Andrew Boulle; Margaret May; Mina Hosseinipour; Eduardo Sprinz; Paula Braitstein; François Dabis; Peter Reiss; David R Bangsberg; Martin Rickenbach; Jose M Miro; Landon Myer; Amanda Mocroft; Denis Nash; Olivia Keiser; Margaret Pascoe; Stefaan van der Borght; Mauro Schechter Journal: Clin Infect Dis Date: 2007-10-22 Impact factor: 9.079
Authors: Julian H Elliott; Khol Vohith; Sarun Saramony; Chin Savuth; Chan Dara; Chel Sarim; Sarah Huffam; Robert Oelrichs; Pouv Sophea; Vonthanak Saphonn; John Kaldor; David A Cooper; Mean Chhi Vun; Martyn A French Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Jonathan E Golub; Paul Pronyk; Lerato Mohapi; Nkeko Thsabangu; Mosa Moshabela; Helen Struthers; Glenda E Gray; James A McIntyre; Richard E Chaisson; Neil A Martinson Journal: AIDS Date: 2009-03-13 Impact factor: 4.177
Authors: Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson Journal: Clin Infect Dis Date: 2014-11-02 Impact factor: 9.079